Shinichi Kageyama

Shinichi Kageyama

Auto-generated profile, based on publicly available information

Shinichi Kageyama

Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MIMikiya Ishihara
Mikiya Ishihara
SKShigehisa Kitano
Shigehisa Kitano
SKShinichi Kageyama
Shinichi Kageyama
YMYoshihiro Miyahara
Yoshihiro Miyahara
NYNoboru Yamamoto
Noboru Yamamoto
HSHiroshi Shiku
Hiroshi Shiku
Background: Because of the shortage of ideal cell surface antigens, the development of T-cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY-ESO-1 is a promising approach for treating patients with solid tumors. However, endogenous TCRs in vector-transduced T cells have been suggested to impair cell-surface expression of transduced TCR while generating mispaired TCRs that can become self-reactive. Methods: We conducted a first-in-human phase I clinical trial with the TCR-transduced T-cell product (TBI-1301) in patients with NY-ESO-1-expressing solid tumors. In manufacturing TCR-T cells, we used a novel affinity-enhanced NY-ESO-1-specific TCR that was transduced by a retroviral vector that enables siRNA (small interfering RNA)-mediated silencing of endogenous TCR. The patients were divided into two cohorts. Cohort 1 was given a dose of 5×108 cells (whole cells including TCR-T cells) preconditioned with 1500 mg/m2 cyclophosphamide. Cohort 2 was given 5× 109 cells preconditioned with 1500 mg/m2 cyclophosphamide. Results: In vitro study showed that both the CD8+ and CD4+ T fractions of TCR-T cells exhibited cytotoxic effects against NY-ESO-1-expressing tumor cells. Three patients and six patients were allocated to cohort 1 and cohort 2, respectively. Three of the six patients who received 5×109 cells showed tumor response, while three patients developed early-onset cytokine release syndrome (CRS). One of the patients developed a grade 3 lung injury associated with the infiltration of the TCR-T cells. No siRNA-related adverse events other than CRS were observed. Cytokines including interleukin 6 I and monocyte chemotactic protein-1/chemokine (C-C motif) ligand (CCL2) increased in the sera of patients with CRS. In vitro analysis showed these cytokines were not secreted from the T cells infused. A significant fraction of the manufactured T cells in patients with CRS was found to express either CD244, CD39, or both at high levels. Conclusions: The trial showed that endogenous TCR-silenced and affinity-enhanced NY-ESO-1 TCR-T cells were safely administered except for grade 3 lung injury. The TCR-T cell infusion exhibited significant tumor response and early-onset CRS in patients with tumors that express NY-ESO-1 at high levels. The differentiation properties of the manufactured T cells may be prognostic for TCR-T-related CRS. Trial registration number: NCT02366546.

22 March 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
Takeshi IshikawaTakeshi Ishikawa
Takeshi Ishikawa
SKShinichi Kageyama
Shinichi Kageyama
YMYoshihiro Miyahara
Yoshihiro Miyahara
TOTetsuya Okayama
Tetsuya Okayama
SKSatoshi Kokura
Satoshi Kokura
HSHiroshi Shiku
Hiroshi Shiku

4 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AKAkira Kawai
Akira Kawai
MIMikiya Ishihara
Mikiya Ishihara
TNTomoki Nakamura
Tomoki Nakamura
SKShigehisa Kitano
Shigehisa Kitano
Shintaro IwataShintaro Iwata
Shintaro Iwata
TUTakafumi Ueda
Takafumi Ueda
Purpose: To determine, for patients with advanced or recurrent synovial sarcoma (SS) not suitable for surgical resection and resistant to anthracycline, the safety and efficacy of the infusion of autologous T lymphocytes expressing NY-ESO-1 antigen-specific T-cell receptor (TCR) gene and siRNA to inhibit the expression of endogenous TCR (product code: TBI-1301). Patients and Methods: Eligible Japanese patients (HLA-A*02:01 or *02:06, NY-ESO-1-positive tumor expression) received cyclophosphamide 750 mg/m2 on days −3 and −2 (induction period) followed by a single dose of 5×109 (±30%) TBI-1301 cells as a divided infusion on days 0 and 1 (treatment period). Primary endpoints were safety-related (phase I) and efficacy-related [objective response rate (ORR) by RECIST v1.1/immune-related RECIST (irRECIST); phase II]. Safety- and efficacy-related secondary endpoints were considered in both phase I/II parts. Results: For the full analysis set (N = 8; phase I, n = 3; phase II, n = 5), the ORR was 50.0% (95% confidence interval, 15.7–84.3) with best overall partial response in four of eight patients according to RECIST v1.1/irRECIST. All patients experienced adverse events and seven of eight patients (87.5%) had adverse drug reactions, but no deaths were attributed to adverse events. Cytokine release syndrome occurred in four of eight patients (50.0%), but all cases recovered with prespecified treatment. Immune effector cell-associated neurotoxicity syndrome, replication-competent retrovirus, and lymphocyte clonality were absent. Conclusions: Adoptive immunotherapy with TBI-1301 to selectively target NY-ESO-1-positive tumor cells appears to be a promising strategy for the treatment of advanced or recurrent SS with acceptable toxicity.

16 April 2022 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YNYasuhiro Nagata
Yasuhiro Nagata
SKShinichi Kageyama
Shinichi Kageyama
TITakeshi Ishikawa
Takeshi Ishikawa
SKSatoshi Kokura
Satoshi Kokura
TOTetsuya Okayama
Tetsuya Okayama
HSHiroshi Shiku
Hiroshi Shiku

1 February 2002 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MMMasahiro Masuya
Masahiro Masuya
NKNaoyuki Katayama
Naoyuki Katayama
KIKoichi Inagaki
Koichi Inagaki
HMHiroshi Miwa
Hiroshi Miwa
NHNatsuki Hoshino
Natsuki Hoshino
HSHiroshi Shiku
Hiroshi Shiku

1 April 2016 in Journal of Urology
Verified
Journal Article
Open access
PDF file
TSTakeshi Sasaki
Takeshi Sasaki
MIMikiya Ishihara
Mikiya Ishihara
HKHideki Kanda
Hideki Kanda
YHYasuhide Hori
Yasuhide Hori
NSNorihito Soga
Norihito Soga
YSYoshiki Sugimura
Yoshiki Sugimura
NY-ESO-1 antigen is a cancer-testis antigen that is exclusively expressed in several types of cancer, aside from expression in the normal testis and placenta. This antigen is considered an ideal target for cancer immunotherapy. Cholesteryl pullulan (CHP) is a novel antigen delivery system. Complexes of CHP and NY-ESO-1 antigen (CHP-NY-ESO-1) present multiple epitope peptides to both the MHC class I and class II pathways. MIS416 is a non-toxic microparticle adjuvant that activates immune responses via NOD-2 and TLR9 pathways. Vaccination studies in mice had demonstrated that CHP-NY-ESO-1 with MIS416 enhanced anti-tumor efficacy. This study evaluated the safety, tolerability, and clinical efficacy of CHP-NY-ESO-1 with adjuvant MIS416 in NY-ESO-1-expressing patients (pts) with refractory urothelial cancer (UC) or castration-resistant prostate cancer (CRPC) (Clinical trial registration number, UMIN000005246).